The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The facts as posted by Gunto
“ Regardless of the outcome of these activities, which are uncertain, the Company’s available resources are sufficient to cover existing committed costs and the estimated costs of these activities
“until at least 30 September 2024”
So we do not know the company will have zero funds after the p2. The next financial statements and updates post P2’s will give us the facts.
Most of the content of this thread is at best highly speculative and at worst blatant misrepresentation by someone who posted a year ago we would run out of money before the end of 2023.
If you want to know financials wait for the financial statement. It will all be explained without any need for guessing.
If someone tells you otherwise, are they Credible and Competent and have the data to be believable
Replying to a colleague on time and delays
"I wish they had the sense of urgency to get us to this stage two years ago," he said.
Duke University Medical Center's Dr. Kanecia Zimmerman, the principal investigator for overseeing the infrastructure of the studies, said
“it had taken time to understand long COVID well enough to design the trials, isolating specific measures to determine whether treatments had succeeded”
It reminds you very much of what Synairgen have had to do in understanding and isolating all the factors that make a patient severely ill from a virus when so many other recover. Particularly as so much of this is cutting edge science.
Synairgen have run many trials so i’m absolutely sure they know how to cost them accurately.
I would expect any new CFO coming into an organisation to review every aspect of the company’s finances, there is nothing unusual about that.
GLA
We can be certain that the board are working hard on behalf of shareholders to deliver the path they set out in the interim statement.
https://synairgen.ams3.digitaloceanspaces.com/230921-Synairgen-Interims_FINAL.pdf
Our new CFO is no doubt reviewing the costs involved in running the new trials and honing the financial strategy that will enable the next phase P3.
If the trials are successful I see no reason why a partner would not be interested in taking this drug forward to commercialisation.
We all need to be patient, await the start of the P2’s which will undoubtedly calm nerves and lead to a steadying of the current SP.
Hopefully this will be our turnaround year.
GLA
Doc83
I think we will all feel easier when we see the detail of the trials.
If we can see highly selective patients groups and early read outs that would be a positive.
Early readouts set a big FOMO for the market. Could data drop that might create a JV will drive a potential lift in the SP.
Trials that say complete in 2025 won’t.
Doc83
I’ll worry about an offer when we have one.
I think a number of Pharma may be interested if we can prove the drug has a target group and I believe that’s been the biggest issue holding us back.
The board tell us they have sufficient funds for these trials so I don’t think they’re running around looking for funds. They are deeply engaged in financing the next phase and as I said that deal in principle might already exist or at least be well advanced.
All of these posts around solvency, selling now at 30p are in my view games being played because we are close to the next news.